Aura Biosciences (AURA) Expected to Announce Quarterly Earnings on Wednesday

Aura Biosciences (NASDAQ:AURA) is anticipated to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect Aura Biosciences to post earnings of ($0.43) per share for the quarter.

Aura Biosciences Price Performance

NASDAQ AURA opened at $7.50 on Monday. The stock has a market capitalization of $374.63 million, a P/E ratio of -4.34 and a beta of 0.30. The firm’s 50-day moving average is $7.66 and its two-hundred day moving average is $8.67. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 23,045 shares of company stock valued at $177,242. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.